Lindbrook Capital LLC Invests $28,000 in Grail, Inc. (NASDAQ:GRAL)

Lindbrook Capital LLC bought a new position in Grail, Inc. (NASDAQ:GRALFree Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,569 shares of the company’s stock, valued at approximately $28,000.

A number of other institutional investors have also recently modified their holdings of GRAL. Douglas Lane & Associates LLC purchased a new stake in shares of Grail in the fourth quarter worth $3,034,000. A. D. Beadell Investment Counsel Inc. purchased a new stake in shares of Grail in the fourth quarter worth $430,000. FNY Investment Advisers LLC purchased a new stake in shares of Grail in the fourth quarter worth $26,000. 180 Wealth Advisors LLC purchased a new stake in shares of Grail in the fourth quarter worth $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Grail in the fourth quarter worth $387,000.

Grail Stock Down 1.7 %

Shares of NASDAQ:GRAL opened at $32.88 on Friday. Grail, Inc. has a 1 year low of $12.33 and a 1 year high of $63.99. The stock’s fifty day moving average price is $30.64 and its 200-day moving average price is $20.84.

Grail (NASDAQ:GRALGet Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.41) by $2.55. The business had revenue of $38.25 million for the quarter, compared to the consensus estimate of $35.33 million. On average, analysts forecast that Grail, Inc. will post -15.15 EPS for the current year.

Wall Street Analysts Forecast Growth

GRAL has been the topic of a number of recent research reports. Wolfe Research initiated coverage on Grail in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Morgan Stanley initiated coverage on Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price target on the stock.

Get Our Latest Research Report on GRAL

Grail Company Profile

(Free Report)

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Featured Articles

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grail, Inc. (NASDAQ:GRALFree Report).

Institutional Ownership by Quarter for Grail (NASDAQ:GRAL)

Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.